Dyne Therapeutics

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / September 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.

Levi & Korsinsky Announces an Investigation on Behalf of Dyne Therapeutics, Inc. (DYN) Shareholders Who May Have Been Affected by Fraud

Investors Who Lost Money on Dyne Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - DYN

NEW YORK CITY, NY / ACCESSWIRE / September 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

Dyne Therapeutics, Inc. (DYN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / September 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.

DYN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Dyne Therapeutics, Inc.

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm In Looking Into Dyne Therapeutics Inc. For Potential Securities Law Violations And Investors Can Reach Out

Dyne Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - DYN

NEW YORK CITY, NY / ACCESSWIRE / September 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc.(DYN) and Encourages Stockholders to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / September 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Dyne Therapeutics, Inc. ("Dyne Therapeutics, Inc.") (NASDAQ:DYN) concerning possible violations of federal securities laws. Dyne issued a press release on September 3, 2024, "announc[ing] new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts.

DYN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Dyne Therapeutics, Inc. investment

LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Dyne Therapeutics Inc May Have Defrauded The Public And Affected Stockholders Should Join The Schall Law Firm's Inquiry

DYN's shares plummet following mixed data from its ongoing DMD study. Senior executives of the company step down.

Dyne Reports Mixed Data From DMD Study, Key Executives Step Down

NEW YORK CITY, NY / ACCESSWIRE / September 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dyne Therapeutics, Inc. ("Dyne" or "the Company") (NASDAQ:DYN). Investors who purchased Dyne securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DYN.

Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc.(DYN) Investors to Inquire about Securities Investigation

Dyne Therapeutics stock crashed Tuesday after several key executives departed on the heels of what the company calls "unprecedented" in DMD.

Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building

Boeing

U.S. stock futures were lower this morning, with the Nasdaq futures dipping around 100 points on Tuesday.

Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

- Building Team to Prepare for Commercialization as Company Pursues Expedited Approval Pathways for DM1 and DMD Clinical Programs -

Dyne Therapeutics Announces Key Leadership Appointments

- Initiating Registrational Cohorts with Update on Path to Registration by Year-End 2024 - - Virtual Investor Event Today at 8:00 a.m. ET -

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on Thursday, September 5, 2024 at 4:05 p.m. ET.

Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

- Recent Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrated Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints -

Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Dyne Therapeutics (DYN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why

Does Dyne Therapeutics, Inc. (DYN) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?

Dyne Therapeutics (DYN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why

WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE™ platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central nervous system (CNS). The data were presented at the New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 23-26 in Fort Lauderdale, FL.

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models -

Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET.

Dyne Therapeutics to Present at Jefferies Global Healthcare Conference

WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the closing of its previously announced underwritten public offering of 12,075,000 shares of its common stock at a public offering price of $31.00 per share, which includes 1,575,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $374.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne. All of the shares in the offering were sold by Dyne.

Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Dyne Therapeutics stock (NASDAQ NASDAQ : DYN), a biotechnology company focused on advancing genetically driven muscle diseases therapeutics, saw a significant 28% rise on Monday, May 20. This move came in after the company released a positive clinical trial data for its experimental drugs – DYNE-101 – for patients with myotonic dystrophy type 1, and DYNE-251 – for patients with Duchenne muscular dystrophy.

News for Dyne Therapeutics Stock (DYN)